GlassScriptPhysician profile
Matilde E Francois
NPI 1124459219
$618.55
in general payments reported to CMS, 2019-2025
12 companies · $106 in 2025
The $106 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $57.54 · 2021: $130 · 2022: $218 · 2023: $107 · 2025: $106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $107 · Food and Beverage: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $107.02 |
| Food and Beverage | $105.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merit Medical Systems INC | $218.42 | 2022 | |
| Lilly USA, LLC | $107.02 | 2023 | Verzenio |
| Ethicon US, LLC | $68.91 | 2019-2021 | |
| Beone Medicines USA, INC. | $44.75 | 2025 | Brukinsa |
| Heron Therapeutics, INC. | $32.65 | 2021 | |
| Coopersurgical, INC. | $31.84 | 2021 | |
| Glaxosmithkline, LLC. | $23.11 | 2025 | Blenrep |
| Exelixis INC. | $20.48 | 2025 | Cabometyx |
| Baudax Bio INC. | $19.69 | 2021 | |
| Convatec INC. | $17.62 | 2021 | |
| Alexion Pharmaceuticals, INC. | $17.20 | 2025 | Ultomiris |
| Merck Sharp & Dohme LLC | $16.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matilde Francois listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.